Long-Term Treatment of Hypertension in Man by an Orally Active Angiotensin-Converting Enzyme Inhibitor

1978 ◽  
Vol 55 (s4) ◽  
pp. 293s-295s ◽  
Author(s):  
H. R. Brunner ◽  
H. Gavras ◽  
G. A. Turini ◽  
B. Waeber ◽  
P. Chappuis ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Enzyme Inhibitor ◽  
Plasma Renin ◽  
Term Treatment ◽  
Hypertensive Patients ◽  
Long Term Treatment ◽  
Treatment Of Hypertension ◽  
Term Administration ◽  
Orally Active

1. Captopril or SQ 14 225, administered orally twice a day, reduced the blood pressure of hypertensive patients whatever their clinical diagnosis and even when their plasma renin activity was ‘normal’ or low. 2. Long-term administration of captopril, either alone or together with diuretics, provides a powerful new tool with which to treat ambulatory hypertensive patients. 3. The renin system may play an important role in maintaining blood pressure in a majority of hypertensive patients.

Landscape of Combination Therapy – Which Way Forward? Proceedings of the Satellite Symposium Held at the ESH European Meeting on Hypertension and Cardiovascular Protection, 27 April 2012, London

2012 ◽  
Vol 8 (3) ◽  
pp. 192
Author(s):  
Patricia Fonseca ◽  
Anna F Dominiczak ◽  
Stephen Harrap ◽  
◽  
◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Risk ◽  
Combination Therapy ◽  
Enzyme Inhibitor ◽  
Synergistic Effects ◽  
Term Treatment ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Patients ◽  
Long Term Treatment

Early combination therapy is more effective for hypertension control in high-risk patients than monotherapy, and current guidelines recommend the use of either an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for first-line therapy in patients younger than 55 years. Recent evidence shows that ACEIs reduce mortality, whereas ARBs show no apparent benefit despite their blood pressure lowering action. However, it is important to consider which blood pressure parameters should be targeted given that different drugs have distinct effects on key parameters. Remarkably, a high percentage of hypertensive patients whose treatment has brought these parameters within target ranges still remain at high risk of cardiovascular disease due to additional risk factors. Combination therapy with synergistic effects on blood pressure and metabolic control should thus be considered for the long-term treatment of hypertensive patients with co-morbid conditions.

Role of antiglucocorticoid RU 486 on dexamethasone-induced hypertension in rats

1989 ◽  
Vol 256 (5) ◽  
pp. E682-E685 ◽  
Author(s):  
M. Kalimi
Keyword(s):  
Blood Pressure ◽  
Term Treatment ◽  
Sprague Dawley ◽  
Ru 486 ◽  
Sprague Dawley Rats ◽  
Long Term Treatment ◽  
Term Administration ◽  
Slight Elevation

This study was conducted to investigate whether hypertension induced by long-term in vivo administration of dexamethasone in rats could be prevented by the newly synthesized potent antiglucocorticoid drug RU 486. Subcutaneous implantation of 5 mg of dexamethasone pellets in Sprague-Dawley rats resulted in a rapid increase in the blood pressure that remained elevated during the 3 wk of experimental observation. RU 486 (50 mg) administered alone surprisingly showed slight elevation of blood pressure over untreated control animals. However, the blood pressure leveled off to control levels over the next 2 wk. Interestingly, a 50-mg RU 486 pellet implanted along with 5 mg of dexamethasone effectively prevented the dexamethasone-induced increase in blood pressure. RU 486 administered together with dexamethasone prevented dexamethasone-induced diuresis and urinary Na+ excretion. However, RU 486 was unable to reverse the weight loss or involution of thymus observed by long-term treatment with dexamethasone alone. No abnormalities were found in either kidneys or hearts in any of the treated groups under microscopic examination. These results suggest that RU 486 successfully prevented the hypertension produced by the long-term administration of dexamethasone in male Sprague-Dawley rats.

scholarly journals A case report of severe hypoaldosteronism following unilateral adrenalectomy for aldosteronoma

2020 ◽  
Vol 13 (4) ◽  
pp. 192-199
Author(s):  
Lilit Egshatyan
Keyword(s):  
Blood Pressure ◽  
Primary Aldosteronism ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Term Treatment ◽  
Unilateral Adrenalectomy ◽  
Hypertensive Patients ◽  
Long Term Treatment ◽  
Risk Patients

Primary aldosteronism is characterized by hypertension and accounts for about 10% of hypertensive patients. Hyperkalemia and renal disease post adrenalectomy has been described in the literature. We present а case of primary aldosteronism with long standing hypertension (more than 10 years) with severe hypokalemia (1.9 mmol/l). Post unilateral adrenalectomy he had reduction in the blood pressure and became eukalemic. However, after 8 weeks of adrenalectomy patient developed hyperkalemia and increased serum creatinine, which resolved with fludrocortisone and attempt to discontinue fludrocortisone resulted in hyperkalemia and rising creatinine. Screening of developing post-operative hyperkalemia should be actively considered in high-risk patients: older age, longer duration of hypertension, higher levels of aldosterone and severe hypokalemia before surgery, impaired estimated glomerular filtration rate and long-term treatment with spironolactone.

Sign in / Sign up

Export Citation Format

Share Document